CytRx Corp. said Thursday that it has begun a pilot Phase IItrial in human volunteers of its TherMax gel, a topicaltherapeutic agent.

The Norcross, Ga., company said the study is intended toinvestigate the safety and efficacy of the drug on pain,inflammation and healing associated with mild to moderateburns. The company said it plans additional Phase II studies insevere burns and for treating certain dermatological conditions.

CytRx had begun Phase I trials in April.

(c) 1997 American Health Consultants. All rights reserved.